Asandeutertinib

Asandeutertinib
Clinical data
Other names	Runnor-9591, TY 9591
Identifiers
	IUPAC name N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-[1-(trideuteriomethyl)indol-3-yl]pyrimidin-2-yl]amino]phenyl]prop-2-enamide;
CAS Number	1638281-46-5;
PubChem CID	87056175;
IUPHAR/BPS	13201;
UNII	9EKD2E8BM5;
Chemical and physical data
Formula	C28H30D3N7O2
Molar mass	502.636 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [2H]C([2H])([2H])N1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC;
	InChI InChI=InChI=1S/C28H33N7O2/c1-7-27(36)30-22-16-23(26(37-6)17-25(22)34(4)15-14-33(2)3)32-28-29-13-12-21(31-28)20-18-35(5)24-11-9-8-10-19(20)24/h7-13,16-18H,1,14-15H2,2-6H3,(H,30,36)(H,29,31,32)/i5D3; Key:DUYJMQONPNNFPI-VPYROQPTSA-N;

Asandeutertinib is an investigational new drug that is being evaluated for the treatment of cancer. It is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with antineoplastic properties.^[1]^[2] Developed by TYK Medicines, this small molecule drug is currently being investigated for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations.^[1]^[3]

References

^ ^a ^b "Asandeutertinib". PatSnap.
^ "Asandeutertinib". IUPHAR/BPS Guide to PHARMACOLOGY.
^ Han B, Zhang W, Wu L, Chen B, Zhao Y, Liu J, et al. (October 2024). "P1. 12A. 07 A Phase 1 Study of TY-9591 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Positive Mutation". Journal of Thoracic Oncology. 19 (10): S195. doi:10.1016/j.jtho.2024.09.353.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.